

Drug Delivery in Central Nervous System Disorders

Technologies, Companies and Markets

By

Prof. K. K. Jain
MD, FRACS, FFPM
Jain PharmaBiotech
Basel, Switzerland

July 2018

A Jain PharmaBiotech Report

A U T H O R ' S B I O G R A P H Y

Professor K. K. Jain is a neurologist/neurosurgeon by training with specialist's qualifications. His personal experience includes some of the technologies mentioned in this report. He received graduate training in both Europe and USA and has held academic positions in several countries. He is a Fellow of the Faculty of Pharmaceutical Medicine of the Royal College of Physicians of UK and has been working in the biotechnology/biopharmaceuticals industry for several years. Currently he is a consultant at Jain PharmaBiotech. Prof. Jain's 476 publications include 30 books (6 as editor + 24 as author) and 50 special reports, which have covered important areas in biotechnology, neurology, and pharmaceuticals.

Prof. Jain has edited "Drug Delivery to the Central Nervous System (Springer/Humana 2010)", and "Drug Delivery Systems", 2nd ed (Springer/Humana 2014); 3rd edition is in preparation for publication in 2019. Most recently he has edited "Applied Neurogenomics" (Springer 2015). Books authored by him include "Handbook of Nanomedicine (Springer 2008, Chinese edition, Peking University Press 2011, 3rd ed Springer 2017)", "Textbook of Personalized Medicine (Springer 2009; Japanese ed 2012; 2nd ed Springer 2015)", "Handbook of Biomarkers (Springer 2010; Chinese edition, Chemical Industry Press, 2016, 2nd ed Springer 2017)", "Handbook of Neuroprotection (Springer 2011, 2nd ed will be published late in 2018)", "Drug-induced Neurological Disorders, 3rd ed (Hogrefe 2011)", "Applications of Biotechnology in Neurology (Springer 2013)", and "Applications of Biotechnology in Oncology (Springer 2014)".

A B O U T T H I S R E P O R T

The original report on Drug Delivery in CNS Diseases by the author was published by Decision Resources Inc in 2000 as an enlargement of the chapter on this topic in his report on Drug Delivery Technologies (1998), which was also published by Decision Resources. The second edition was rewritten and published at Jain PharmaBiotech in 2004 and is being constantly rewritten since then.

**July 2018 (constantly updated since first edition published in 2000 by Decision Resources Inc)
Copyright © 2018 by**

**Jain PharmaBiotech
Bläsiring 7
CH-4057 Basel
Switzerland**

**Tel & Fax: +4161-6924461
Email: info@pharmabiotech.ch
Web site: http://pharmabiotech.ch/**

All rights reserved. No part of this publication may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying, or otherwise without the prior written permission of the Publisher. This report may not be lent, resold or otherwise traded in any manner without the consent of the Publisher. While all reasonable steps have been taken to ensure the accuracy of the information presented, the Publisher cannot accept responsibility for inadvertent errors or omissions.

TABLE OF CONTENTS

0. Executive Summary	17
1. Basics of Drug Delivery to the Central Nervous System	19
Introduction	19
Historical evolution of drug delivery for CNS disorders.....	19
Neuroanatomical and neurophysiological basis of drug delivery.....	20
The cerebrospinal fluid	20
The lymphatic drainage system of the brain	21
The extracellular space in the brain	21
Neurotransmitters.....	22
Extracellular vesicles as drug delivery vehicles	24
Neuropharmacology relevant to drug delivery.....	24
Introduction to neuropharmacology.....	24
Pharmacokinetics.....	24
<i>Absorption and distribution of drugs</i>	<i>24</i>
<i>Drug metabolism and elimination.....</i>	<i>25</i>
Pharmacodynamics	25
<i>Receptors</i>	<i>25</i>
Sites of drug action in the CNS	25
<i>Receptors coupled to guanine nucleotide binding proteins</i>	<i>26</i>
<i>Acetylcholine receptor channels</i>	<i>26</i>
<i>Dopamine receptors.....</i>	<i>26</i>
<i>GABA receptor channels.....</i>	<i>27</i>
<i>Glutamate receptor channels.....</i>	<i>27</i>
<i>Non-competitive NMDA antagonists.....</i>	<i>27</i>
<i>Serotonin receptors.....</i>	<i>28</i>
<i>G-protein coupled receptors</i>	<i>28</i>
In vivo study of drug action in the CNS in human patients	28
<i>Electroencephalography.....</i>	<i>28</i>
<i>Brain imaging.....</i>	<i>29</i>
Chronopharmacology as applied to the CNS	29
Role of drug delivery in personalized therapy of CNS disorders	30
2. Blood Brain Barrier	31
Introduction	31
Features of the blood-brain barrier relevant to CNS drug delivery.....	31
The neurovascular unit	31
Functions of the BBB	32
<i>BBB as an anatomical as well as physiological barrier</i>	<i>32</i>
<i>BBB as a biochemical barrier</i>	<i>33</i>
<i>Glucose transporters at the BBB</i>	<i>33</i>
Role of shear stress on development of BBB.....	34
Genomics of BBB	34
Proteomics of BBB.....	35
Other neural barriers	35
Blood-cerebrospinal fluid barrier	35
Blood nerve barrier	36
Blood-retinal barrier	36
Blood-labyrinth barrier	36
Passage of substances across the blood-brain barrier	36
Transporters localized in the BBB	37
<i>Adenosine carrier.....</i>	<i>38</i>
<i>Amino acid transporters.....</i>	<i>38</i>
<i>Amino acid transporters.....</i>	<i>38</i>
<i>Amino acid transporters.....</i>	<i>38</i>
<i>Efflux transport systems</i>	<i>39</i>
<i>Glucose transporter.....</i>	<i>40</i>
<i>Ionic transporter.....</i>	<i>40</i>
BBB-specific enzymes.....	41
Receptor-mediated transcytosis	41
Lysophosphatidic acid-mediated increase in BBB permeability	42
Folate transport system	42
Transferrin receptor	42
Molecular biology of the BBB	42
Transport of peptides and proteins across the BBB.....	43
<i>Passage of leptin across the BBB.....</i>	<i>43</i>
<i>Passage of cytokines across the BBB</i>	<i>43</i>
<i>Passage of hormones across the BBB</i>	<i>44</i>
<i>Passage of enzymes across the BBB</i>	<i>44</i>

Passage of omega-3 fatty acids across the BBB	45
<i>Drugs that cross the BBB by binding to plasma proteins</i>	45
Current concepts of the permeability of the BBB	45
Factors that increase the permeability of the BBB	46
BBB disruption as an adverse effect of pharmaceuticals	46
BBB disruption as adverse effect of vaccines for CNS disorders	47
CNS disorders and BBB	47
Autoimmune disorders.....	48
Brain tumors	48
<i>Primary brain tumors</i>	48
<i>Cerebral metastases</i>	48
Central nervous system injuries.....	49
Cerebrovascular disease	49
<i>Cerebral ischemia</i>	49
<i>Intracerebral hemorrhage</i>	49
Epilepsy.....	50
Infections	50
Mitochondrial encephalopathies	51
Multiple sclerosis.....	51
Neurodegenerative disorders	52
<i>BBB in Alzheimer disease</i>	52
<i>BBB in Parkinson disease</i>	54
<i>BBB in amyotrophic lateral sclerosis</i>	54
West Nile virus infection	54
Testing permeability of the BBB.....	54
In vitro models of BBB.....	55
In vivo study of BBB.....	56
<i>Brain imaging</i>	56
In silico prediction of BBB	57
Relevance of the BBB penetration to pharmacological action	58
<i>BBB penetration and CNS drug screening</i>	58
<i>BBB models for testing drug delivery</i>	58
<i>CERENSESM</i>	59
<i>In vivo brain distribution of P-glycoprotein</i>	59
Transthyretin monomer as a marker of blood-CSF barrier disruption	60
Evaluation of BBB permeability by brain imaging	60
Biomarkers of disruption of blood-brain barrier.....	60
Future directions for research on the BBB	60
Use of neural stem cells to construct the blood brain barrier.....	61
Strategies to cross the BBB.....	62
3. Methods of Drug Delivery to the CNS	63
Introduction	63
Routes of drug delivery to the brain	64
Drug deliveries to the brain via the nasal route	64
<i>Devices for nasal administration of drugs for CNS</i>	66
<i>Nasal mucosal patch to facilitate drug delivery across the BBB</i>	66
<i>Passage of viruses to the brain via the nasal route</i>	66
<i>Potential and limitations of nasal drug delivery to the brain</i>	67
Drugs that can be delivered to the brain via the nasal route.....	67
<i>Erythropoietin</i>	67
<i>Esketamine</i>	67
<i>Hypocretin</i>	68
<i>IFN beta-1b</i>	68
<i>Lysosomal enzymes</i>	68
<i>Midazolam</i>	68
<i>Neurotrophic factors</i>	69
<i>Thyrotropin-releasing hormone</i>	69
<i>Neuroprotective drugs for stroke</i>	70
Transdermal drug delivery for neurological disorders.....	70
Drug delivery to the brain via inner ear	71
Drug delivery for disorders of the spinal cord.....	71
Intrathecal drug delivery.....	71
<i>Anatomical & physiological aspects of intrathecal drug delivery</i>	71
<i>Advantages of intrathecal drug delivery</i>	72
<i>Drugs that can be delivered by intrathecal route</i>	72
<i>Pharmacokinetics of intrathecal drug delivery</i>	73
<i>Retrograde delivery to the brain via the epidural venous system</i>	75
Devices for drug delivery to the CNS	75
<i>Catheters for drug delivery to the CNS</i>	75
<i>Reservoirs and pumps for drug delivery to the CNS</i>	76

Invasive neurosurgical approaches.....	77
<i>Intraarterial drug delivery to the brain.....</i>	77
<i>Direct injection into the CNS substance or CNS lesions</i>	77
<i>Targeted delivery of biologicals to the spinal cord by microinjection</i>	78
<i>Intraventricular injection of drugs</i>	78
Strategies for drug delivery to the CNS across the BBB	79
Increasing the permeability (opening) of the BBB	79
<i>Osmotic opening of the BBB</i>	79
<i>Focal disruption of BBB by ultrasound.....</i>	80
<i>Chemical opening of the BBB.....</i>	80
<i>Cerebral vasodilatation to open the BBB</i>	80
<i>Modulation of vascular permeability by laser irradiation</i>	81
<i>Neurostimulation for opening BBB.....</i>	81
<i>Use of nitric oxide donors to open the BBB.....</i>	82
<i>Manipulation of the sphingosine 1-phosphate receptor system.....</i>	82
Pharmacological strategies to facilitate transport across the BBB	82
<i>2B-Trans™ technology.....</i>	83
<i>ABC afflux transporters and penetration of the BBB.....</i>	83
<i>Adenosine agonist-mediated drug delivery across the BBB</i>	84
<i>Carrier-mediated drug delivery across the BBB.....</i>	84
<i>Fusion of receptor-binding peptide from apoE with therapeutic protein</i>	85
<i>G-Technology®</i>	85
<i>Glycosylation Independent Lysosomal Targeting</i>	86
<i>Inhibition of P-glycoprotein to enhance drug delivery across the BBB</i>	86
<i>LipoBridge™ technology.....</i>	87
<i>Modification of the drug to enhance its lipid solubility</i>	87
<i>Monoclonal antibody fusion proteins</i>	87
<i>Neuroimmunophilins.....</i>	88
<i>Peptide-mediated transport across the BBB.....</i>	88
<i>Prodrug bioconversion strategies and their CNS selectivity</i>	90
<i>Transport of small molecules across the BBB.....</i>	91
<i>Transport across the BBB by short chain oligoglycerolipids</i>	91
<i>Transvascular delivery across the BBB.....</i>	91
<i>Trojan horse approach.....</i>	91
<i>Role of the transferrin-receptor system in CNS drug delivery.....</i>	92
<i>Use of receptor-mediated transcytosis to cross the BBB</i>	92
Cell-based drug delivery to the CNS	94
<i>Activated T lymphocytes.....</i>	95
<i>Microglial cells.....</i>	95
<i>Neural stem cells.....</i>	95
Drug delivery to the CNS by using novel formulations.....	95
<i>Crystalline formulations</i>	95
<i>Liposomes.....</i>	95
<i>Monoclonal antibodies</i>	97
<i>Microspheres.....</i>	97
<i>Microbeads.....</i>	98
Brain-targeted chemical delivery systems	98
Nanotechnology-based drug delivery to CNS	99
Nanoparticles for drug delivery across the BBB	99
<i>NanoDel™ technology for crossing the BBB</i>	100
<i>Masking BBB-limiting characteristics by nanotechnology</i>	100
<i>Nanovesicles for transport across BBB</i>	100
<i>Peptide-nanoparticle conjugates for crossing the BBB.....</i>	100
<i>Penetration of BBB by nanoparticles coated with polysorbate 80</i>	101
<i>Targeting nicotinic acetylcholine receptor.....</i>	101
<i>Transcytosis of transferrin-containing nanoparticles across the BBB</i>	101
Nanotechnology-based devices and implants for CNS	102
Biochip implants for drug delivery to the CNS.....	102
Controlled-release microchip	102
Retinal implant chip	102
Convection-enhanced delivery to the CNS	103
Systemic administration of drugs for CNS effects	104
Sustained and controlled release drug delivery to the CNS	104
<i>Fast dissolving oral selegiline.....</i>	105
Choice of the route of systemic delivery for effect on the CNS disorders	106
Methods of delivery of biopharmaceuticals to the CNS	106
Delivery of biopharmaceuticals across the BBB	106
Methods of delivery of peptides for CNS disorders.....	107
<i>Alteration of properties of the BBB for delivery of peptides</i>	107
<i>Challenges for delivery of peptides across the BBB.....</i>	107
<i>CNS delivery of peptides via conjugation to biological carriers</i>	108

<i>Delivery of conopeptides to the brain</i>	108
<i>Direct delivery of neuropeptides into the brain</i>	108
<i>Molecular manipulations of peptides to facilitate transport into CNS</i>	109
<i>Transport to spinal cord motor neurons after peripheral injection</i>	109
<i>Transnasal administration of neuropeptides</i>	110
Delivery of neurotrophic factors to the nervous system.....	110
<i>Systemic administration of NTFs</i>	112
<i>Delivery systems to facilitate crossing of the BBB by NTFs</i>	112
<i>Direct application of NTFs to the CNS</i>	113
<i>Intracerebroventricular injection</i>	113
<i>Intrathecal administration</i>	114
<i>Implants for delivery of neurotrophic factors</i>	114
<i>Use of neurotrophic factor mimics</i>	115
<i>Use of microspheres for delivery of neurotrophic factors</i>	116
<i>Use of nanobiotechnology for delivery of neurotrophic factors</i>	116
Use of microorganisms for therapeutic entry into the brain	117
Bacteriophages as CNS therapeutics.....	117
Intracellular drug delivery in the brain	117
Local factors in the brain affecting drug action	118
Methods for testing drug delivery to the CNS	118
Animal models for testing drug delivery	118
Screening for drug-P-gp interaction at BBB	118
4. Delivery of Cell, Gene and Antisense Therapies to the CNS	121
Introduction	121
Cell therapy of neurological disorders	121
Methods for delivering cell therapies in CNS disorders	121
<i>Cerebrospinal fluid-stem cell interactions for therapy of CNS disorders</i>	122
<i>Engineered stem cells for drug delivery to the brain</i>	122
<i>Encapsulated cells</i>	123
<i>Intrathecal delivery of stem cells</i>	123
<i>Intraparenchymal delivery of stem cells to the spinal cord</i>	124
<i>Intravascular administration</i>	124
<i>Neural stem cells as therapeutic delivery vehicles</i>	125
Gene therapy techniques for the nervous system	125
Introduction	125
Methods of gene transfer to the nervous system	127
AAV vector mediated gene therapy for neurogenetic disorders.....	127
Ideal vector for gene therapy of neurological disorders	127
Promoters of gene transfer.....	128
Routes of delivery of genes to the nervous system.....	128
<i>Direct injection into CNS</i>	128
<i>Introduction of the genes into cerebral circulation</i>	129
<i>Introduction of genes into cerebrospinal fluid</i>	129
<i>Intravenous administration of vectors</i>	130
<i>Delivery of gene therapy to the peripheral nervous system</i>	130
Cell-mediated gene therapy of neurological disorders	130
<i>Neuronal cells</i>	130
<i>Neural stem cells and progenitor cells</i>	130
<i>Astrocytes</i>	131
<i>Cerebral endothelial cells</i>	131
<i>Implantation of genetically modified encapsulated cells into the brain</i>	131
<i>Genetically modified bone marrow cells</i>	131
Nanoparticles as nonviral vectors for CNS gene therapy.....	132
Applications of gene therapy for neurological disorders.....	132
Companies involved in cell/gene therapy of neurological disorders	133
Antisense therapy of CNS disorders	134
Delivery of antisense oligonucleotides to the CNS	135
Delivery of oligonucleotides cross the BBB	136
Cellular delivery systems for oligonucleotides	137
High-flow microinfusion into the brain parenchyma	137
Systemic administration of peptide nucleic acids.....	137
Introduction of antisense compounds into the CSF Pathways	138
Intrathecal administration of antisense compounds	138
Intracerebroventricular administration of antisense oligonucleotides.....	138
Nanoparticle-based delivery of antisense therapy to the CNS.....	139
Methods of delivery of ribozymes	139
Delivery aspects of RNAi therapy of CNS disorders	140
Delivery of siRNA to the CNS	140
Future drug delivery strategies applicable to the CNS	141

5. Drug Delivery for Treatment of Neurological Disorders	143
Introduction	143
Targeted drug delivery for neurological disorders	143
Parkinson's disease	143
Drug delivery systems for Parkinson's disease	145
<i>Methods of delivery of levodopa in PD</i>	<i>146</i>
<i>Duodenal levodopa infusion.....</i>	<i>146</i>
<i>Sublingual apomorphine</i>	<i>147</i>
<i>Transdermal drug delivery for PD.....</i>	<i>147</i>
<i>Transdermal dopamine agonists for PD</i>	<i>147</i>
<i>Transdermal administration of other drugs for PD</i>	<i>149</i>
<i>Intracerebral administration of GDNF</i>	<i>149</i>
Cell therapy for PD.....	149
<i>Human dopaminergic neurons for PD.....</i>	<i>150</i>
<i>Graft survival-enhancing drugs.....</i>	<i>151</i>
<i>Xenografting porcine fetal neurons.....</i>	<i>151</i>
<i>Encapsulated cells for PD</i>	<i>152</i>
<i>Stem cells for PD</i>	<i>152</i>
<i>Engineered stem cells for drug delivery to the brain in PD</i>	<i>153</i>
<i>Human retinal pigment epithelium cells for PD.....</i>	<i>154</i>
<i>Delivery of cells for PD.....</i>	<i>154</i>
Gene therapy for Parkinson disease.....	155
<i>Rationale</i>	<i>155</i>
<i>Techniques of gene therapy for PD.....</i>	<i>156</i>
<i>Prospects of gene therapy for PD</i>	<i>159</i>
<i>Companies developing gene therapy for PD.....</i>	<i>160</i>
RNAi therapy of Parkinson's disease	160
Alzheimer disease.....	161
Drug delivery for Alzheimer disease	161
Blood-brain partitioning of an AMPA receptor modulator	162
Clearing amyloid through the BBB.....	163
Delivery of the passive antibody directly to the brain.....	163
Delivery of thyrotropin-releasing hormone analogs by molecular packaging.....	163
Nanoparticle-based drug delivery for Alzheimer's disease.....	163
Perispinal etanercept.....	164
Slow release implant of an AChE inhibitor	165
Intranasal insulin in Alzheimer disease	165
Transdermal drug delivery in Alzheimer's disease.....	165
Trojan-horse approach to prevent build-up of A β aggregates.....	166
Cell and gene therapy for Alzheimer disease.....	166
<i>NGF gene therapy.....</i>	<i>166</i>
<i>Neprilysin gene therapy</i>	<i>167</i>
RNAi therapy of Alzheimer's disease	168
Huntington's disease	168
Treatment of HD	168
Gene therapy of HD	169
<i>Encapsulated genetically engineered cellular implants.....</i>	<i>169</i>
<i>Viral vector mediated administration of neurotrophic factors</i>	<i>169</i>
<i>RNAi therapeutics for the treatment of HD</i>	<i>169</i>
Amyotrophic lateral sclerosis.....	170
Treatment of ALS.....	170
Drug delivery in ALS.....	170
Delivery of stem cell therapy for ALS.....	171
Gene and antisense therapy of ALS	172
<i>Neurotrophic factor gene therapies of ALS.....</i>	<i>172</i>
<i>Antisense therapy of ALS</i>	<i>174</i>
<i>RNAi therapy of amyotrophic lateral sclerosis</i>	<i>174</i>
Cerebrovascular disease	174
Treatment of stroke	175
Drug delivery in stroke	175
<i>Intraarterial administration of tissue plasminogen activator in stroke.....</i>	<i>176</i>
Drug delivery for prevention of restenosis of carotid arteries	177
<i>In-stent restenosis.....</i>	<i>177</i>
<i>Targeted local anti-restenotic drug delivery.....</i>	<i>178</i>
<i>Catheter-based drug delivery for restenosis</i>	<i>178</i>
<i>Stents for prevention of restenosis.....</i>	<i>179</i>
<i>Drug-eluting stents</i>	<i>179</i>
<i>Antisense approach to prevent restenosis</i>	<i>180</i>
Drug-eluting stents for the treatment of intracranial atherosclerosis.....	180
Tissues transplants for stroke.....	181
<i>Transplant of encapsulated tissue secreting neurotrophic factors</i>	<i>181</i>

Methods for delivery of neurotrophic factors in stroke.....	181
Cell therapy for stroke.....	181
<i>Stem cell transplant into the brain</i>	182
<i>Immortalized cell grafts for stroke</i>	182
<i>Intravenous infusion of marrow stromal cells</i>	183
<i>Intravenous infusion of umbilical cord blood stem cells</i>	183
<i>Future of cell therapy for stroke</i>	183
Gene therapy of cerebrovascular diseases.....	183
<i>Gene transfer to cerebral blood vessels</i>	184
<i>NOS gene therapy for restenosis</i>	185
Gene therapy for cerebral ischemia.....	185
<i>Gene therapy of strokes with a genetic component</i>	187
Drug delivery to intracranial aneurysms.....	187
Drug delivery for vasospasm following subarachnoid hemorrhage.....	187
<i>Intrathecal tissue plasminogen activator</i>	188
<i>Gene therapy for vasospasm</i>	189
Drug delivery in multiple sclerosis.....	190
An electronic device for self injection of interferon beta-1a.....	190
Oral therapies for MS.....	190
Drug delivery for MS across the BBB.....	191
<i>Delivery of methylprednisolone across the BBB</i>	191
<i>Monoclonal antibodies for MS and the BBB</i>	191
Antisense and RNAi approaches to MS.....	191
Cell therapy for multiple sclerosis.....	192
<i>Hematopoietic stem cell transplantation for multiple sclerosis</i>	192
<i>Embryonic stem cells and neural precursor cells for MS</i>	193
Gene therapy for multiple sclerosis.....	193
Drug delivery in epilepsy.....	193
Routes of administration of antiepileptic drugs.....	194
<i>Controlled-release preparations of carbamazepine</i>	194
<i>Intravenous carbamazepine</i>	194
<i>Various routes of administration of benzodiazepines</i>	195
Methods of delivery of novel antiepileptic therapies.....	195
<i>Regulated activation of prodrugs</i>	195
<i>Use of neuronal membrane transporter</i>	195
<i>Delivery of the antiepileptic conopeptides to the brain</i>	196
<i>Nasal administration of AEDs</i>	196
<i>Intracerebral administration of AEDs</i>	196
The role of drug delivery in status epilepticus.....	197
Cell therapy of epilepsy.....	198
Gene therapy for epilepsy.....	198
<i>Gene therapy for neuroprotection in epilepsy</i>	199
Concluding remarks on drug delivery in epilepsy.....	199
Drug delivery for pain.....	200
Intranasal delivery of analgesics.....	201
<i>Intranasal administration of morphine</i>	201
<i>Intranasal morphine derivatives</i>	201
<i>Intranasal fentanyl</i>	202
<i>Intranasal buprenorphine</i>	203
<i>Intranasal ketamine</i>	203
<i>Intranasal ketorolac</i>	203
Delivery of analgesics by inhalation.....	203
Delivery of analgesics to peripheral nerves.....	204
Spinal delivery of analgesics.....	205
<i>Epidural dexamethasone</i>	207
<i>Epidural morphine</i>	207
<i>Relief of pain by intrathecal ziconotide</i>	207
<i>Intrathecal neostigmine</i>	208
<i>Intrathecal prostaglandin antagonists</i>	208
<i>Intrathecal fadolmidine</i>	208
<i>Intrathecal siRNA for relief of neuropathic pain</i>	209
<i>Concluding remarks on intrathecal delivery of analgesic agents</i>	209
Intracerebroventricular drug delivery for pain.....	209
<i>Delivery of analgesics to the CNS across the BBB</i>	209
Drug delivery for migraine.....	210
Management of migraine.....	210
Novel drug delivery methods for migraine.....	211
<i>Nasal formulations for migraine</i>	212
<i>Sublingual spray for migraine</i>	212
<i>Needle-free drug delivery for migraine</i>	213
Drug delivery for traumatic brain injury.....	213

Cell therapy of traumatic brain injury	213
<i>Gene therapy for traumatic brain injury</i>	214
Drug delivery for spinal cord injury	214
Administration of neurotrophic factors for spinal cord injury	214
Cell therapy for spinal cord injury	215
<i>Transplantation of glial cells for SCI</i>	215
<i>Fetal neural grafts for SCI</i>	215
<i>Embryonic stem cells for SCI</i>	215
<i>Schwann cell transplants for SCI</i>	216
<i>Olfactory glial cells for SCI</i>	216
<i>Marrow stromal cells for SCI</i>	217
<i>Intravenous injection of stem cells for spinal cord repair</i>	217
<i>Combinatorial approach for regeneration in SCI</i>	217
<i>Cell therapy of syringomyelia</i>	218
<i>Gene therapy of spinal cord injury</i>	218
Drug delivery in CNS infections.....	218
Drug delivery in neuroAIDS	219
Drug delivery for miscellaneous neurological disorders.....	219
Drug delivery for CNS involvement in Hunter syndrome	219
<i>Trojan horse therapeutics to treat mucopolysaccharidosis types I & II</i>	220
Antisense therapy for spinal muscular atrophy.....	221
<i>Antisense gene splicing for SMA</i>	221
<i>Intrathecal antisense delivery</i>	221
Genetically modified stem cells for metachromatic leukodystrophy	221
Relief of spasticity by intrathecal baclofen	221
Drug delivery for retinal disorders.....	222
<i>Age-related macular degeneration</i>	222
<i>Squalamine</i>	223
<i>Combretastatin A4P for myopic macular degeneration</i>	223
<i>Gene therapy for AMD</i>	223
<i>Anti-VEGF approach to AMD</i>	224
<i>Delivery of pegaptanib for treatment of AMD</i>	224
Stem cell therapy for retinitis pigmentosa	224
Proliferative retinopathies	225
Drug delivery for inner ear disorders.....	225
Delivery of stem cells for hearing loss.....	225
Auditory hair cell replacement by gene therapy	226
Future prospects of drug delivery to the inner ear	226
Drug delivery in psychiatric disorders.....	227
Delivery of antidepressants	227
<i>Transdermal delivery of antidepressants</i>	228
<i>Nasal delivery of antidepressants</i>	230
Delivery methods and formulations of antipsychotics.....	230
<i>Long-acting injectable antipsychotics</i>	230
<i>Transdermal haloperidol</i>	231
<i>Transdermal risperidone for treatment of schizophrenia</i>	231
<i>Transdermal blonanserin for treatment of schizophrenia</i>	232
<i>Transnasal oxytocin for schizophrenia</i>	232
Transdermal lithium for bipolar disorder	232
6. Drug delivery for brain tumors	233
Introduction	233
Methods for evaluation of anticancer drug penetration into brain tumor	233
Innovative methods of drug delivery for glioblastoma multiforme.....	233
Delivery of anticancer drugs across the blood-brain barrier	234
Anticancer agents with increased penetration of BBB.....	234
BBB disruption.....	235
Nanoparticle-based targeted delivery of chemotherapy across the BBB.....	236
Tyrosine kinase inhibitor increases topotecan penetration into CNS	237
Bypassing the BBB by alternative methods of drug delivery	238
Intranasal perillyl alcohol	238
Intraarterial chemotherapy	238
Enhancing tumor permeability to chemotherapy	239
PDE5 inhibitors for increasing BTB permeability	239
Local delivery of therapeutic agents into the brain	239
Biodegradable microspheres containing 5-FU.....	239
Carmustine biodegradable polymer implants	240
Fibrin glue implants containing anticancer drugs.....	241
Interstitial delivery of dexamethasone for reduction of peritumor edema	241
Magnetically controlled microspheres.....	241
Convection-enhanced delivery	241

CED for receptor-directed cytotoxin therapy	241
CED of topotecan	242
CED of a modified diphtheria toxin conjugated to transferrin	242
CED of nanoliposomal CPT-11.....	242
CED for delivery ¹³¹ I-chTNT-1/B MAb	243
Anticancer drug formulations for targeted delivery to brain tumors	243
Intravenous delivery of anticancer agents bearing transferrin	243
Liposomes for drug delivery to brain tumors.....	243
MAbs targeted to brain tumors	244
Targeted delivery of drug-peptide conjugates to GBM.....	244
Multiple targeted drugs for brain tumors	245
Nanoparticles for targeted drug delivery in glioblastoma multiforme	245
Targeted antiangiogenic/apoptotic/cytotoxic therapies.....	246
Targeted drug delivery to gliomas using cholera toxin subunit B	247
Introduction of the chemotherapeutic agent into the CSF pathways	247
Intraventricular chemotherapy for meningeal cancer	247
Intrathecal chemotherapy	248
Photodynamic therapy for chemosensitization of brain tumors	248
Nanoparticles for photodynamic therapy of brain tumors.....	249
Innovative delivery of radiotherapy to brain tumors	249
GliaSite Radiation Therapy System.....	249
Boron neutron capture therapy for brain tumors	249
Cell therapy for glioblastoma multiforme.....	250
Chimeric antigen receptor T cells	250
Mesenchymal stem cells to deliver treatment for gliomas.....	250
Gene therapy for glioblastoma multiforme.	250
Antiangiogenic gene therapy	252
Anticancer drug delivery by genetically engineered MSCs.....	252
Intravenous gene delivery with nanoparticles into brain tumors.....	252
Ligand-directed delivery of dsRNA molecules targeted to EGFR.....	253
Neural stem cells for drug/gene delivery to brain tumors	253
Peptides targeted to glial tumor cells.....	254
RNAi gene therapy of brain cancer	254
Single-chain antibody-targeted adenoviral vectors	254
Targeting normal brain cells with an AAV vector encoding interferon-β	255
Poliovirus-based vaccine for glioblastoma.....	255
Treatment of medulloblastoma by suppressing genes in Shh pathway	256
Virus-mediated oncolytic therapy of brain cancer	257
<i>HIV-mediated Oncolysis.....</i>	<i>257</i>
<i>Autophagy by conditionally replicating adenoviruses.....</i>	<i>257</i>
<i>Reovirus-mediated Oncolysis.....</i>	<i>258</i>
<i>Measles virus-mediated oncolysis.....</i>	<i>258</i>
<i>Oncolytic virus targeted to brain tumor stem cells.....</i>	<i>258</i>
<i>Oncolysis with vesicular stomatitis virus</i>	<i>259</i>
<i>Future prospects of viral-mediated oncolysis</i>	<i>259</i>
Vaccination for glioblastoma multiforme	259
7. Markets for Drug Delivery in CNS Disorders.....	261
Introduction	261
Methods of calculation of CNS drug delivery markets.....	261
Markets for CNS drug delivery technologies	261
Drug delivery share in selected CNS markets.....	262
CNS share of drug delivery technologies	262
Geographical distribution of CNS drug delivery markets	263
Impact of improved drug delivery on CNS drug markets.....	263
Neurodegenerative disorders.....	263
<i>Alzheimer disease</i>	<i>264</i>
<i>Parkinson disease</i>	<i>264</i>
<i>Huntington disease</i>	<i>264</i>
<i>Amyotrophic lateral sclerosis</i>	<i>264</i>
Epilepsy.....	265
Migraine and other headaches	265
Stroke	265
Central nervous system trauma	266
Multiple sclerosis.....	266
Brain tumors	266
Limitations of the current drug delivery technologies for CNS	267
Unmet needs in CNS drug delivery technologies	267
Regulatory considerations for drugs that cross the BBB	268
Public-private collaboration for transfer of research to the clinic	269
Future strategies for expanding CNS drug delivery markets.....	269

Education of neurologists	269
Demonstration of the advantages of the newer methods of delivery	270
Rescue of old products by novel drug delivery methods	270
Facilitation of the approval process of new drugs	270

8. Companies	271
Introduction	271
Profiles of companies.....	271
2-BBB Medicines BV	271
AbbVie Inc	274
Acorda Therapeutics Inc	275
Alexza Pharmaceuticals	276
Alkermes	277
Alnylam Pharmaceuticals Inc	279
Alseres Pharmaceuticals Inc	280
ALZA	281
Amgen Inc	283
AngioChem Inc	284
ArmaGen Technologies Inc	285
AstraZeneca	287
Bayer Pharma AG.....	288
Biogen Idec.....	289
BiOasis Technologies Inc.....	290
Biovail Corporation.....	291
BrainsGate Ltd.....	292
Cell Cure Neurosciences Ltd	293
Celtic Pharma Management LP.....	294
CepTor Corporation	295
Codman.....	296
Cynapsus Therapeutics Inc.....	297
Direct Therapeutics Inc.....	298
D-Pharm.....	299
DURECT Corporation	300
Elan Corporation plc.....	301
Endovasc Ltd.....	302
Ethypharm SA	303
Garnet BioTherapeutics Inc	304
GenVec Inc	305
ImaRx Therapeutics Inc.....	306
Intra-Cellular Therapies Inc.....	307
IVAX Corporation	308
Living Cell Technologies Ltd.....	309
MedGenesis Therapeutix Inc.....	310
Medtronic Inc	311
MGI Pharma Inc.....	312
MRI Interventions	313
NanoDel Technologies GmbH.....	314
NanoMed Pharmaceuticals Inc	315
Neurologix Inc.....	316
NeuroNova AB	318
Neurorecovery Inc	319
Neurotech SA	320
NEUWAY Pharma GmbH.....	321
NsGene	322
NuPathe Inc	323
Oxford Biomedica plc.....	324
Pharmidex	325
Pherin Pharmaceuticals Inc	326
Raptor Pharmaceuticals Corporation	327
REGENXBIO Inc	328
ReNeuron (UK) Ltd.....	330
Sagetis Biotech.....	331
Sangamo BioSciences Inc	332
Sanofi	333
Sanofi Genzyme	334
Sarepta Therapeutics	335
Schwarz Pharma	337
Shire Plc	338
Spherics Inc	340
StemCells Inc	341
Sumitomo Dainippon Pharma Co Ltd	342

Synt:em	344
Tapestry Pharmaceuticals Inc	345
Theradigm Inc	346
Therataxis LLC.....	347
Titan Pharmaceuticals Inc	348
Upsher-Smith Laboratories Inc	349
Valeant Pharmaceuticals International	350
Valerion Therapeutics LLC	351
Vasogen Inc.....	352
VECT-HORUS SAS	353
Voyager Pharmaceutical Corporation	354
XenoPort Inc	355
Collaborations.....	357

9. References..... 361

Tables

Table 1-1: Landmarks in the development of drug delivery to the CNS	19
Table 2-1: Proteins expressed at the neurovascular unit.....	32
Table 2-2: Transporters that control penetration of molecules across the BBB	37
Table 2-3: Enzymes that control the penetration of molecules across the BBB	41
Table 2-4: Factors that increase the permeability of the BBB.....	46
Table 2-5: Diseases with associated disturbances of BBB.....	47
Table 3-1: Various methods of drug delivery to the central nervous system	63
Table 3-2: Drugs available for intrathecal administration	73
Table 3-3: Investigational drugs administered by intrathecal route	73
Table 3-4: Strategies for drug delivery to the CNS across the BBB	79
Table 3-5: Specific inhibitors of P-glycoprotein in clinical development	86
Table 3-6: Molecules attached to Trojan horses injected intravenously for CNS effect.....	91
Table 3-7: Examples of controlled and sustained release drug delivery for CNS disorders	105
Table 3-8: Novel methods of delivery of drugs for CNS disorders	106
Table 3-9: Indications for the clinical applications of NTFs in neurologic disorders.....	110
Table 3-10: Methods for delivery of neurotrophic factors to the CNS	111
Table 4-1: Methods for delivering cell therapies in CNS disorders.....	122
Table 4-2: Classification of methods of gene therapy.....	126
Table 4-3: Methods of gene transfer as applied to neurologic disorders	127
Table 4-4: Potential indications for gene therapy of neurologic disorders	132
Table 4-5: Companies developing cell/gene therapies for CNS disorders	134
Table 4-6: Methods of antisense delivery as applied to the CNS.....	135
Table 5-1: Strategies for the treatment of Parkinson's disease	143
Table 5-2: Drug delivery systems for Parkinson's disease	145
Table 5-3: Types of cell used for investigative treatment of Parkinson's disease	150
Table 5-4: Status of cell therapies in development for Parkinson's disease	150
Table 5-5: Gene therapy techniques applicable to Parkinson disease	156
Table 5-6: Companies developing gene therapy for Parkinson's disease.....	160
Table 5-7: Classification of pharmacotherapy for Alzheimer disease	161
Table 5-8: Novel drug delivery methods for Alzheimer disease therapies	162
Table 5-9: Classification of neuroprotective agents for amyotrophic lateral sclerosis.....	170
Table 5-10: Methods of delivery of therapies in development for ALS	171
Table 5-11: Classification of treatments for stroke	175
Table 5-12: Treatments of stroke involving innovative drug delivery methods	176
Table 5-13: Drug delivery for prevention of carotid artery restenosis after angioplasty	178
Table 5-14: Gene transfer in animal models of carotid artery restenosis	184
Table 5-15: Neuroprotective gene transfer strategies in models of cerebral ischemia	185
Table 5-16: Gene Therapy for reducing cerebral infarction in animal stroke models.....	186
Table 5-17: Pharmacological agents for treatment of cerebral vasospasm.....	188
Table 5-18: Gene therapy strategies for vasospasm.....	189
Table 5-19: A classification of drug delivery methods used in management of pain	200
Table 5-20: Spinal administration of drugs for pain	205
Table 5-21: Investigational drugs for pain administered by intrathecal route	205
Table 5-22: Current management of migraine	210
Table 5-23: Novel drug delivery methods for migraine	211
Table 6-1: Innovative methods of drug delivery for glioblastoma multiforme	233
Table 6-2: Strategies for gene therapy of malignant brain tumors.....	251
Table 7-1: Share of drug delivery technologies in selected CNS markets: 2017-2027	262
Table 7-2: CNS market share of drug delivery technologies 2017-2027	262
Table 7-3: Value of CNS drug delivery in the major world markets from 2017-2027.....	263
Table 7-4: Limitations of the current drug delivery technologies for CNS.....	267
Table 8-1: Alkermes pipeline.....	278
Table 8-2: Collaborations of companies in CNS drug delivery	357

Figures

Figure 1-1: Interaction of neurotransmitters with receptors	23
Figure 2-1: The neurovascular unit	31
Figure 2-2: Various forms of passage of substances across the blood brain barrier.....	37
Figure 2-3: Role of BBB models for drug delivery in preclinical CNS drug development	59
Figure 3-1: Routes of drug delivery to the brain	64
Figure 3-2: Extracellular mechanism for drug transportation to the brain following intranasal administration.....	65
Figure 3-3: Penetration of CSF into spinal cord	72
Figure 3-4: Disposition of opioids after intrathecal administration	74
Figure 3-5: Use of receptor-mediated transcytosis to cross the BBB	93
Figure 3-6: Nanotechnology-based strategies for delivery of BDNF to the CNS	117
Figure 5-1: Oral versus transdermal administration of a drug in Parkinson's disease	148
Figure 5-2: Effect of tyrosine hydroxylase gene delivery on dopamine levels	157
Figure 5-3: Trojan horse approach for delivery of AGT-181 to the brain.....	220
Figure 6-1: A concept of targeted drug delivery to GBM across the BBB.....	236
Figure 6-2: Mechanism of antitumor effects of poliovirus-based vaccine for glioblastoma	256
Figure 7-1: Unmet needs in the CNS drug delivery technologies	268